News
All NewsBlogs
Media
All VideosCase-Based Roundtable SeriesEichenbaum AcornsExpert InterviewsEyeviewsInsightsMedical World NewsPodcastsRapid ReadoutsThe Retina TL;DRViewpoints
Conference
Conference CoverageConference Listing
Publications
Modern Retina Digital EditionSupplements And Featured Publications
More
Resources
Between the LinesCME/CEEYLEA 8mg for nAMD and DME TreatmentSponsored Resources
Partners

Subscribe

  • News
  • Media
  • Conference
  • Publications
  • Resources
  • Partners
  • Subscribe
  • AMD
    • Wet AMD
  • Biosimilar
  • Diabetic Macular Edema
    • Diabetic Eye Awareness
  • Diabetic Retinopathy
  • Geographic Atrophy
  • Imaging
  • Inherited Retinal Diseases
  • Ophthalmology
    • Europe
  • RVO
  • Retina Technology
  • Retinal Surgery
  • Uveitis
Spotlight -
Geographic Atrophy
Advertisement

Mathew W. MacCumber, MD, PhD

Advertisement

Articles by Mathew W. MacCumber, MD, PhD

eye injections

IRIS Registry study: Overall anti-VEGF injection intervals for wet AMD similar at 1, 2 years of treatment

ByMathew W. MacCumber, MD, PhD
March 3rd 2020
Advertisement

Latest Updated Articles

  • eye injections
    IRIS Registry study: Overall anti-VEGF injection intervals for wet AMD similar at 1, 2 years of treatment

    March 3rd 2020



Advertisement
Advertisement

Trending on Modern Retina

1

Directional OCT provides biomarkers of Parkinson’s Disease in the outer retina

2

FDA grants RMAT designation to RTx-015 optogenetic gene therapy for retinitis pigmentosa

3

Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD

4

OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study

  • About
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us